PTEN and neoplasm: The latter 5 parameters were further examined by multivariate regression analysis, which showed treatment history, pathological type and PTEN expression group independently predicted reduced PFS, and higher tumor progression risk was detected for PTEN low group compared with PTEN high group SBCs (p = 0.006), consistent with protein level data (Table 3).